The fibrosis in kidney tissue, as well as in other tissues, is greatly mediated by the TGF-β pathway, and the inhibition of TGF-β is a major target for therapeutic approaches against chronic kidney disease associated with fibrosis [3,5] and other fibrotic diseases in general [55]. Here, TGFB1 is linked to chronic kidney disease.